SCHEMBL2260726

SCHEMBL2260726

COC(=O)c1cc(Cl)nc(-c2ccc(C)cc2F)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP46A1 Q9Y6A2 1/20 0.45
HDAC1 Q13547 4/20 0.43
KDM1A O60341 3/20 0.43
ALDH1A1 P00352 4/20 0.43
ALPL P05186 2/20 0.41
HDAC2 Q92769 1/20 0.41
HDAC11 Q96DB2 1/20 0.41
HDAC8 Q9BY41 1/20 0.41
HDAC6 Q9UBN7 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
PTGES O14684 1/20 0.40
KDM4E B2RXH2 3/20 0.38
DHODH Q02127 1/20 0.38
MAPT P10636 3/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
HSD17B10 Q99714 2/20 0.38
NPC1 O15118 2/20 0.38
RAB9A P51151 2/20 0.38
HPGD P15428 1/20 0.38
NFKB1 P19838 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25691350 0.80 MAPT (0.50) ALDH1A1ALPLTDP1KDM4EDHODH
SCHEMBL14479830 0.79 KDM4E (0.53) ALDH1A1TDP1KDM4EMAPTSMN1; SMN2
SCHEMBL29371765 0.79 KDM4E (0.53) ALDH1A1TDP1KDM4EMAPTSMN1; SMN2
SCHEMBL20727093 0.77 CYP46A1 (0.42) CYP46A1HDAC1KDM1AALDH1A1ALPL
SCHEMBL2260701 0.76 PIK3CA (0.51) CYP46A1ALDH1A1KDM4EMAPTSMN1; SMN2
SCHEMBL16533700 0.76 NPC1 (0.51) ALDH1A1KDM4EDHODHMAPTSMN1; SMN2
SCHEMBL30007819 0.76 NPC1 (0.51) ALDH1A1KDM4EDHODHMAPTSMN1; SMN2
SCHEMBL16533246 0.75 MAPT (0.49) ALDH1A1ALPLMAPTSMN1; SMN2NPC1
SCHEMBL24492367 0.75 KDM4A (0.49) ALDH1A1TDP1KDM4EMAPTSMN1; SMN2
SCHEMBL29465815 0.75 KDM4A (0.49) ALDH1A1TDP1KDM4EMAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2860178-B1 P2X3 receptor antagonists for treatment of pain MERCK SHARP & DOHME (US) 2021-01-13 EP disclosed
EP-2860178-A2 P2X3 receptor antagonists for treatment of pain Merck Sharp & Dohme Corp. (US) 2015-04-15 EP disclosed
EP-2358371-B1 P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN MERCK SHARP & DOHME (US) 2015-02-11 EP disclosed
US-8598209-B2 P2X3, receptor antagonists for treatment of pain MERCK SHARP & DOHME CORP. (US) 2013-12-03 US disclosed
US-20110206783-A1 P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN MERCK SHARP & DOHME LLC 2011-08-25 US disclosed
EP-2358371-A1 P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN Merck Sharp & Dohme Corp. (US) 2011-08-24 EP disclosed
WO-2010051188-A1 P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN MERCK SHARP & DOHME CORP. (US) 2010-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110206783-A1 P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN P2RX3, P2RX1, P2RX2 CYP46A1 4537/4885HDAC1 3459/4885KDM1A 3570/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.